3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Cisplatin
21
Etoposide
20
Carboplatin
20
Topotecan
13
pembrolizumab
12
durvalumab
11
Paclitaxel
10
Irinotecan
9
Nivolumab
7
Gemcitabine
7
tremelimumab
6
atezolizumab
6
Radiotherapy
6
Docetaxel
6
Pemetrexed
5
Ipilimumab
5
Cyclophosphamide
5
rovalpituzumab tesirine
4
budigalimab
4
Specimen Handling
4
Injections
4
Doxorubicin
4
Bortezomib
4
130-nm albumin-bound paclitaxel
4
venetoclax
3
talazoparib
3
olaparib
3
fludarabine
3
etoposide phosphate
3
Platinum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Small Cell Lung Carcinoma
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled